Claims
- 1. A method of increasing antimicrobial effect localized to activated immune system cells of a host currently emitting oxidants while reducing cytotoxicity to host cells, comprising:
administering an effective amount of an allium-related organosulfur compound, wherein said organosulfur compound, when so administered, results in a localized thiosulfinate being non-enzymatically formed in response to localized generation of H2O2 by the activated immune system cells.
- 2. The method of claim 1 wherein said thiosulfinate is allicin.
- 3. The method of claim 1 wherein said administration of said allium-related organosulfur compound is through the use of a prodrug.
- 4. The method of claim 3 where said prodrug is SAMC.
- 5. The method of claim 3 where said prodrug is protein bound SAMC.
- 6. A method of enhancing beneficial immune system response in a host, comprising:
administering an effective amount of an allium-related organosulfur compound, wherein said organosulfur compound, when so administered, results in localized thiosulfinate being non-enzymatically formed in response to localized generation of H2O2 by activated immune system cells of the host.
- 7. The method of claim 6 wherein said thiosulfinate is allicin.
- 8. The method of claim 6 wherein said administration of said allium-related organosulfur compound is by delivery by a prodrug.
- 9. The method of claim 8 where said prodrug is SAMC.
- 10. The method of claim 8 where said prodrug is protein bound SAMC.
- 11. A method of enhancing beneficial immune system response in a host, comprising:
simultaneouly delivering to the host a plurality of organosulfur compounds selected from the group of cysteine, cystine, N-acetylcysteine, and allium-related compounds, through the use of one or more prodrugs, said prodrugs producing at least one such compound capable of being converted to an active pharmacological agent in response to H2O2 emitted by the host's activated immune system cells.
- 12. A method of avoiding pathology in a host, comprising:
administering to the host an antioxidant, wherein the antioxidant is converted to a pro-oxidant by one or more oxidants naturally generated by the host's immune system, said pro-oxidant having at least one beneficial property relative to said naturally generated oxidants.
- 13. A method of prophylactic and therapeutic treatment of infectious disease and pathology resulting from immune system activation in a host, comprising:
administering an effective amount of SAMC to the host sufficient to prevent, reduce, or eliminate the infectious disease or pathology of immune system response.
- 14. The method of claim 13 wherein a prophylactically effective amount of SAMC is administered.
- 15. The method of claim 14 wherein said prophylactically effective amount comprises an amount in the range of 0.1 to 50 mg.
- 16. The method of claim 13 wherein a therapeutically effective amount of SAMC is administered.
- 17. The method of claim 16 wherein said therapeutically effective amount comprises an amount in the range of 10 mg to 14,000 mg.
- 18. The method of claim 13 where the pathology is due to chronic immune system activation.
- 19. The method of claim 18 wherein a therapeutically effective amount of SAMC is administered.
- 20. The method of claim 13 wherein said effective amount of SAMC includes an effective amount of a protein-bound SAMC.
- 21. The method of claim 20 wherein said effective amount of SAMC consists essentially of an effective amount of a protein-bound SAMC.
- 22. The method of claim 21 wherein a prophylactically effective amount of said protein-bound SMAC is administered.
- 23. The method of claim 22 wherein said prophylactically effective amount comprises an amount in the range of 0.1 to 50 mg.
- 24. The method of claim 21 wherein a therapeutically effective amount of protein-bound SAMC is administered in range of 10 mg to 14,000 mg.
Parent Case Info
[0001] This application claims the benefit of provisional application No. 60/472,791, filed May 23, 2003.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60472791 |
May 2003 |
US |